Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct;52(10):3000605241279190.
doi: 10.1177/03000605241279190.

Impact of microRNAs on cardiovascular diseases and aging

Affiliations
Review

Impact of microRNAs on cardiovascular diseases and aging

Md Sayed Ali Sheikh et al. J Int Med Res. 2024 Oct.

Abstract

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality for both men and women among all ethnicities worldwide. Although significant improvements in the management of CVD occurred in the 20th century, non-invasive, universal, early diagnostic biomarkers and newer therapeutic drugs are needed for clinical treatment by physicians. MicroRNAs (miRNAs) are a class of endogenous, non-coding, single-stranded, small RNA molecules that are critically controlled by all human biological processes. Moreover, dysregulated miRNA expression is directly involved in various CVDs, including stable coronary artery disease and acute coronary syndrome. Several miRNAs that are enriched in the plasma of CVD patients have potential as clinical biomarkers, and overexpression or inhibition of specific miRNAs has novel therapeutic significance in the management of CVD. Aging is a multifactorial physiological process that gradually deteriorates tissue and organ function and is considered a non-modifiable major risk factor for CVDs. Recently, several studies established that various miRNAs essentially regulate aging and aging-related disease processes. This narrative review briefly discusses the recently updated molecular involvement of miRNAs in CVDs, their possible diagnostic, prognostic, and therapeutic value, and their relationship to the aging process.

Keywords: Cardiovascular disease; aging; diagnosis; microRNA; prognosis; therapeutic.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestThe authors declare that there is no conflict of interest.

Similar articles

Cited by

References

    1. Martin SS, Aday AW, Almarzooq ZI, et al.. Heart Disease and Stroke Statistics-2024 Update: a report from the American Heart Association. Circulation 2024; 149: e347–e913. - PubMed
    1. Harold EB, Anandita K, Charles G, et al.. Ten things to know about ten cardiovascular disease risk factors – 2022. Am J Prev Cardiol 2022; 6: 100342. - PMC - PubMed
    1. Ali Sheikh MS, Alduraywish A, Almaeen A, et al.. Therapeutic value of miRNAs in coronary artery disease. Oxid Med Cell Longev 2021; 2021: 8853748. - PMC - PubMed
    1. Szydełko J, Matyjaszek-Matuszek B. MicroRNAs as biomarkers for coronary artery disease related to type 2 diabetes mellitus—from pathogenesis to potential clinical application. Int J Mol Sci 2023; 24: 616. - PMC - PubMed
    1. González-López P, Álvarez-Villarreal M, Ruiz-Simón R, et al.. Role of miR-15a-5p and miR-199a-3p in the inflammatory pathway regulated by NF-κB in experimental and human atherosclerosis. Clin Transl Med 2023; 13: e1363. - PMC - PubMed

LinkOut - more resources